Hampton Lee M, Daubresse Matthew, Chang Hsien-Yen, Alexander G Caleb, Budnitz Daniel S
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
Center for Drug Safety and Effectiveness, The Johns Hopkins University, Baltimore, Maryland3Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
JAMA Psychiatry. 2014 Sep;71(9):1006-14. doi: 10.1001/jamapsychiatry.2014.436.
In 2011, an estimated 26.8 million US adults used prescription medications for mental illness.
To estimate the numbers and rates of adverse drug event (ADE) emergency department (ED) visits involving psychiatric medications among US adults between January 1, 2009, and December 31, 2011.
Descriptive analyses of active, nationally representative surveillance of ADE ED visits using the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance system and of drug prescribing during outpatient visits using the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey.
Medical records from national probability samples of ED and outpatient visits by adults 19 years or older were reviewed and analyzed.
Antidepressants, antipsychotics, lithium salts, sedatives and anxiolytics, and stimulants.
National estimates of ADE ED visits resulting from therapeutic psychiatric medication use and of psychiatric medication ADE ED visits per 10,000 outpatient visits at which psychiatric medications were prescribed.
From 2009 through 2011, there were an estimated 89,094 (95% CI, 68,641-109,548) psychiatric medication ADE ED visits annually, with 19.3% (95% CI, 16.3%-22.2%) resulting in hospitalization and 49.4% (95% CI, 46.5%-52.4%) involving patients aged 19 to 44 years. Sedatives and anxiolytics, antidepressants, antipsychotics, lithium salts, and stimulants were implicated in an estimated 30,707 (95% CI, 23,406-38,008), 25,377 (95% CI, 19,051-31,704), 21,578 (95% CI, 16,599-26,557), 3620 (95% CI, 2311-4928), and 2779 (95% CI, 1764-3794) respective ADE ED visits annually. Antipsychotics and lithium salts were implicated in 11.7 (95% CI, 10.1-13.2) and 16.4 (95% CI, 13.0-19.9) ADE ED visits per 10,000 outpatient prescription visits, respectively, compared with 3.6 (95% CI, 3.2-4.1) for sedatives and anxiolytics, 2.9 (95% CI, 2.3-3.5) for stimulants, and 2.4 (95% CI, 2.1-2.7) for antidepressants. The commonly used sedative zolpidem tartrate was implicated in 11.5% (95% CI, 9.5%-13.4%) of all adult psychiatric medication ADE ED visits and in 21.0% (95% CI, 16.3%-25.7%) of visits involving adults 65 years or older, in both cases significantly more than any other psychiatric medication.
Psychiatric medications are implicated in many ADEs treated in US EDs. Efforts to reduce ADEs should include adults of all ages but might prioritize medications causing high numbers and rates of ED visits.
2011年,估计有2680万美国成年人使用治疗精神疾病的处方药。
估算2009年1月1日至2011年12月31日期间,美国成年人因使用精神科药物而导致不良药物事件(ADE)并前往急诊科(ED)就诊的人数及发生率。
采用国家电子伤害监测系统-合作不良药物事件监测系统,对ADE急诊就诊情况进行全国性、具有代表性的主动监测,并利用国家门诊医疗调查和国家医院门诊医疗调查对门诊就诊时的药物处方进行描述性分析。
对19岁及以上成年人急诊和门诊就诊的全国概率样本的病历进行回顾和分析。
抗抑郁药、抗精神病药、锂盐、镇静催眠药和抗焦虑药以及兴奋剂。
全国范围内因使用治疗性精神科药物导致的ADE急诊就诊估计数,以及每10000次开具精神科药物的门诊就诊中因精神科药物ADE而前往急诊就诊的次数。
2009年至2011年期间,估计每年有89094例(95%可信区间为68641 - 109548例)因精神科药物ADE而前往急诊就诊,其中19.3%(95%可信区间为16.3% - 22.2%)导致住院,49.4%(95%可信区间为46.5% - 52.4%)涉及19至44岁的患者。镇静催眠药和抗焦虑药、抗抑郁药、抗精神病药、锂盐以及兴奋剂每年分别导致估计30707例(95%可信区间为23406 - 38008例)、25377例(95%可信区间为19051 - 31704例)、21578例(95%可信区间为16599 - 26557例)、3620例(95%可信区间为2311 - 4928例)和2779例(95%可信区间为1764 - 3794例)的ADE急诊就诊。每10000次门诊处方就诊中,抗精神病药和锂盐分别导致11.7例(95%可信区间为10.1 - 13.2例)和16.4例(95%可信区间为13.0 - 19.9例)ADE急诊就诊,而镇静催眠药和抗焦虑药为3.6例(95%可信区间为3.2 - 4.1例),兴奋剂为2.9例(95%可信区间为2.3 - 3.5例),抗抑郁药为2.4例(95%可信区间为2.1 - 2.7例)。常用的镇静催眠药酒石酸唑吡坦涉及所有成年精神科药物ADE急诊就诊的11.5%(95%可信区间为9.5% - 13.4%),涉及65岁及以上成年人就诊的21.0%(95%可信区间为16.3% - 25.7%),在这两种情况下均显著高于任何其他精神科药物。
在美国急诊科治疗的许多ADE中都涉及精神科药物。减少ADE的努力应涵盖所有年龄段的成年人,但可能应优先关注导致大量急诊就诊及高发生率的药物。